13 June 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use of obecabtagene autoleucel in the NHS in England.

For the time being, obecabtagene autoleucel should not be used for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia.

Read NICE draft guidance consultation